

SUPPLEMENTAL DIGITAL CONTENT 10

This table also appears in the Supplemental Digital Content 2 in the complete set of evidence tools.

Table 9. Vasopressin compared to other vasopressors in patients with septic shock

Author(s): Alshamsi F, Alhazzani W, Singer M

Date: October 7 2016

Question: Vasopressin compared to other pressors in patients with septic shock

Setting: ICU

Bibliography: Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PloS one. 2015 Aug 3;10(8):e0129305.

No of studies	Study design	Quality assessment					No of patients		Effect		Quality	Importance
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Vasopressin	other pressors	Relative (95% CI)	Absolute (95% CI)		
Mortality												
9	randomized trials	not serious	not serious	not serious ¹	serious ²	none ³	273/674 (40.5%)	293/650 (45.1%)	RR 0.89 (0.79 to 1.00)	50 fewer per 1,000 (from 0 fewer to 95 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
							40.0% ⁴	44 fewer per 1,000 (from 0 fewer)				

											to 84 fewer)		
--	--	--	--	--	--	--	--	--	--	--	-----------------	--	--


CI: Confidence interval; **RR:** Risk ratio

1. Although there was some indirectness at the intervention level, majority of trials used a combination of AVP or terlipressin with norepinephrine in the intervention arm, however, a sensitivity analysis excluding these studies did not significantly affect the quality of evidence or direction of treatment effect, therefore, we did not downgrade for indirectness
2. The CI interval included significant benefit and crossed the unity line, therefore, we downgraded the quality of evidence for imprecision by one level
3. We could not reliably assess for publication bias due to small number of included studies
4. Data on septic shock mortality from Sepsis-3

Figure 2. Vasopressin compared to other vasopressors in patients with septic shock

Mortality Outcome (9 RCTs 1234 patients)

Study or Subgroup	Vasopressin/Terlipressin		Other vasopressors		Weight	Risk Ratio		Year
	Events	Total	Events	Total		IV, Random, 95% CI		
Diinser 2003	7	24	7	24	1.9%	1.00 [0.41, 2.42]	2003	
Albanese 2005	5	10	4	10	1.5%	1.25 [0.47, 3.33]	2005	
Lauzier 2006	2	13	1	10	0.3%	1.54 [0.16, 14.66]	2006	
Russet 2008	172	392	188	379	63.8%	0.88 [0.76, 1.03]	2008	
Morelli 2008	12	19	14	20	7.3%	0.90 [0.58, 1.41]	2008	
Morelli 2009	15	30	10	15	5.7%	0.75 [0.45, 1.24]	2009	
Han 2012	27	66	34	73	10.1%	0.88 [0.60, 1.28]	2012	
Hua 2013	7	16	8	16	2.7%	0.88 [0.42, 1.84]	2013	
Gordon 2016	26	104	27	103	6.8%	0.95 [0.60, 1.52]	2016	
Total (95% CI)		674		650	100.0%	0.89 [0.79, 1.00]		
Total events	273		293					
Heterogeneity: Tau ² = 0.00; Chi ² = 1.30, df = 8 (P = 1.00); I ² = 0%								
Test for overall effect: Z = 1.91 (P = 0.06)								



IV: Inverse variance